KPV Peptide: Research Overview, Purity Data and Where to Buy

Strip alpha-melanocyte-stimulating hormone (alpha-MSH) down to its last three amino acids and what remains is KPV: lysine-proline-valine, a tripeptide with a molecular weight of roughly 342 g/mol. The pigmentation signalling that defines the parent hormone disappears at that length. The anti-inflammatory activity described across published cell and rodent models largely doesn't. That mismatch is the entire reason KPV carries its own body of research instead of sitting as a footnote inside melanocortin papers.

We supply research-grade peptides to laboratories and independent investigators, and the questions we field about KPV are rarely about biology. They're about paperwork. What's actually in the vial, who verified it, and whether the documentation survives scrutiny. All products are sold for laboratory research use only and are not for human consumption.

What is KPV?

KPV is a synthetic tripeptide composed of lysine, proline and valine, corresponding to residues 11 to 13 of alpha-MSH. Published research examines it primarily as an anti-inflammatory signalling molecule in intestinal, dermal and antimicrobial model systems. It ships as a lyophilised white powder and is handled strictly as a research chemical with per-lot analytical documentation.

The common oversimplification is that KPV is simply alpha-MSH minus the unwanted effects. That framing skips the mechanism that makes the fragment worth studying at all. PepT1, an oligopeptide transporter expressed on intestinal epithelial and immune cells, carries intact di- and tripeptides across the cell membrane, which means a three-residue sequence can reach intracellular targets that bulkier molecules cannot. This page covers what KPV is structurally, what the indexed literature examines, how material is stored and verified, where it sits in regulatory terms, and how to order it for laboratory work.

A three-amino-acid fragment of a melanocortin hormone

KPV is the C-terminal tripeptide of alpha-MSH, which is itself cleaved from POMC (proopiomelanocortin), the precursor protein that also yields ACTH and beta-endorphin. The sequence is Lys-Pro-Val, molecular formula C16H30N4O4. Because it carries none of the residues responsible for melanocortin receptor driven pigmentation, KPV is studied as an anti-inflammatory fragment rather than a melanotropic one.

The mechanism described across the alpha-MSH and NF-kB literature indexed on PubMed centres on NF-kB (nuclear factor kappa-B), the transcription factor complex that switches on pro-inflammatory genes including TNF-alpha, IL-1beta and IL-6. Research in that area reports reduced nuclear translocation of NF-kB in stimulated cells, which lowers cytokine output broadly rather than blocking a single receptor. KPV appears in that same line of work as the minimal active fragment.

The uptake route deserves more attention than most summaries give it. The PepT1 transporter literature on PubMed describes PepT1 as the entry pathway for KPV into colonic epithelial cells and macrophages. PepT1 expression is low in healthy colonic tissue and upregulated in inflamed tissue, so in model systems the delivery is partly self-concentrating at the site that expresses the transporter. Our team has answered this question more than any other: that transporter detail, not the amino acid sequence, is the part of the KPV story people get wrong.

What the published literature actually examines

The indexed research on KPV clusters into three areas: intestinal inflammation, dermal and wound models, and direct antimicrobial activity. All of it is preclinical. None of it establishes a therapeutic use in people.

The largest cluster is gastrointestinal. The colitis research indexed on PubMed uses chemically induced colitis models in rodents and cultured intestinal epithelial lines, and a substantial portion of the more recent work focuses on delivery engineering rather than the peptide itself, including hydrogel and nanoparticle carriers designed to release the tripeptide in the colon. Researchers report reduced inflammatory markers and improved histological scores in these models, which is a model-system observation and not a clinical endpoint.

A second cluster covers skin. The dermal and wound literature on PubMed examines keratinocyte and fibroblast responses, contact hypersensitivity models, and inflammatory skin models where the parent melanocortin pathway is already implicated. This is where most cosmetic-adjacent interest in KPV originates, usually well ahead of what the evidence supports.

A third, smaller cluster is antimicrobial. The antimicrobial research indexed on PubMed reports activity of alpha-MSH and its C-terminal fragment against organisms including Candida albicans and Staphylococcus aureus in vitro, at concentrations that don't map cleanly onto anything systemic.

How should that be read honestly? Research suggests an anti-inflammatory signalling profile that is consistent across several independent model systems. It does not demonstrate efficacy in humans, and KPV has not been evaluated in the large randomised controlled trials that would be required to make any such claim.

Laboratory handling, storage and what the label mass really means

Lyophilised KPV is supplied as a freeze-dried powder and is stored frozen, typically at -20C, protected from light and moisture. The powder is hygroscopic, which means it pulls water out of ambient air, and moisture is the practical enemy of a tripeptide far more than heat is during short transit. Short ambient exposure during shipping is normal and expected for lyophilised material; prolonged exposure is not.

Once a lot is in solution, the handling rules tighten considerably. Solutions are kept refrigerated at 2 to 8C, protected from light, and repeated freeze-thaw cycles are avoided because each cycle concentrates solutes at the ice interface and accelerates degradation. Aliquoting on first preparation, rather than returning to a single vial repeatedly, is the standard way laboratories avoid that problem with KPV and with every other small peptide.

Here's the detail almost nobody checks, and it's the one that quietly ruins comparability between labs. The mass printed on a vial is gross peptide mass, not net peptide content. A lyophilised peptide carries residual water and counterions, commonly trifluoroacetate left over from purification, and those contribute real weight. Material can be highly pure by chromatography and still be meaningfully less than its labelled mass in actual peptide. Two laboratories working from identically labelled vials of KPV, sourced from suppliers with different workup chemistry, can be comparing results that were never on the same scale to begin with. Net peptide content is the number that reconciles them.

How purity gets verified, lot by lot

Purity verification for KPV rests on two independent analyses that answer two different questions. HPLC (high-performance liquid chromatography) answers how much of the peptide-related material in the vial is the target compound, reported as area percent. Mass spectrometry, usually ESI-MS, answers whether that compound is the correct molecule by confirming the expected mass of the Lys-Pro-Val sequence against the observed mass.

Neither test is useful without the other. Chromatography can show a clean single peak for the wrong sequence. Mass confirmation can identify the right molecule in material that also contains deletion sequences or synthesis byproducts. A certificate that reports only one of the two is reporting half an answer, and a certificate that reports neither against a specific lot number is marketing copy.

Per-lot testing is the part that gets compressed by suppliers under cost pressure. One certificate reused across multiple synthesis batches tells you nothing about the vial in your hand, because peptide synthesis varies batch to batch by nature. Every lot we release is synthesised in small batches with the amino acid sequence verified, and the corresponding analytical documentation is published in our certificates of analysis library so the lot number on the vial can be matched against its own test data rather than a generic sample. When researchers ask us what separates reliable KPV from unreliable KPV, this is the whole answer.

Regulatory status and ordering for laboratory use

KPV has not been approved by the FDA as a drug product for any indication, and it is not a dietary supplement ingredient, a cosmetic ingredient with an approved monograph, or a veterinary medicine. It is a research chemical. That classification governs how it is labelled, sold, shipped and used, and it is not a technicality that disappears if a buyer intends otherwise.

The practical consequence is that legitimate suppliers restrict sale to research and laboratory contexts and say so in writing on the listing, the invoice and the vial label. The information on this page is educational and describes published research and laboratory practice only. Anyone with questions about an animal's health should raise them with their veterinarian, and anyone with questions about their own health should raise them with a licensed physician. A peptide supplier is the wrong party for either conversation.

For laboratory procurement, our KPV listing ships as lyophilised powder with the lot-specific certificate available before purchase, and researchers working on adjacent tripeptide chemistry frequently pair it with GHK-Cu, the copper-binding tripeptide studied in overlapping dermal models. Our broader research catalog lists the full range under the same small-batch synthesis and documentation standard.

KPV sourcing: what to compare before you buy

Most suppliers look identical on a product page. The differences show up in documentation, and this table lays out where to look and what a weak answer actually costs a laboratory.

What If: Sourcing and Handling Scenarios

What if the vial looks almost empty when it arrives?

Check the certificate for the stated mass before assuming anything went wrong. Lyophilised tripeptides at single-digit milligram quantities form a film or a few flakes on the vial wall or stopper, not a visible pile, because the freeze-drying process removes essentially all water and leaves very little bulk. Material displaced onto the stopper during transit is normal and is recovered when the vial is brought back to volume.

What if a shipment sat in a hot vehicle or on a doorstep for a day?

Contact the supplier with the lot number rather than guessing at the material's condition. Lyophilised KPV is considerably more tolerant of short ambient excursions than a solution would be, which is precisely why it ships dry, but the relevant variable is cumulative exposure to heat and humidity rather than a single peak temperature. Nothing visible on the vial distinguishes intact peptide from partially degraded peptide.

What if the certificate doesn't match the lot number on the vial?

Stop and request the matching document before using the material. A mismatch means the analytical data describes a different synthesis batch, and batch-to-batch variation in peptide synthesis is normal enough that substituting one certificate for another invalidates the comparison. Suppliers who cannot produce lot-matched paperwork on request are not running per-lot testing, whatever the product page claims.

What if you found KPV while researching a pet's gut health?

That conversation belongs with your veterinarian, not with a peptide supplier. KPV is not an approved veterinary medicine, and nothing published about rodent colitis models transfers directly to a companion animal's care. A veterinarian can assess the actual condition and discuss treatments that have been evaluated for that species.

The uncomfortable truth about purity claims

Let's be direct about this: a 99% purity figure on a product page means almost nothing on its own. Purity is reported relative to the peptide-related material detected by a specific chromatographic method, not relative to everything in the vial, and the method, the run conditions and the lot it applies to all change what the number means. A supplier who publishes a lot-matched chromatogram and a mass spectrum at 98% is giving you more usable information than one who prints 99.9% with nothing behind it. Verify the document, not the adjective.

Researchers comparing sources can review our published certificates of analysis, the documented purity standards behind our small-batch synthesis, the KPV product page itself, and the wider catalog for adjacent research compounds.

KPV is interesting precisely because of how little of the original hormone it keeps. Three residues, no melanocortin pigmentation signalling, and a body of preclinical work suggesting the anti-inflammatory part of the message survives the truncation. That's a genuinely elegant piece of peptide chemistry, and it's also exactly why the documentation matters so much: at three amino acids, a single deletion or a counterion load you weren't told about changes the experiment entirely, and no amount of careful technique downstream recovers what was wrong in the vial. All products are sold for laboratory research use only and are not for human consumption.